Retinal toxicity of recombinant tissue plasminogen activator in the rabbit
- PMID: 2105712
- DOI: 10.1001/archopht.1990.01070040111042
Retinal toxicity of recombinant tissue plasminogen activator in the rabbit
Abstract
We studied the dose-dependent retinal toxicity of the available commercial preparation of human recombinant tissue plasminogen activator in the normal rabbit eye. Tissue plasminogen activator was injected into the midvitreous cavity of albino rabbits in doses (per 100 microL) of 25, 50, 75, and 100 micrograms. Control eyes received 100 microL of balanced salt solution or tissue plasminogen activator vehicle. No evidence of a retinal toxic reaction was seen in eyes receiving 25 micrograms of tissue plasminogen activator. One of four eyes injected with 50 micrograms showed loss of photoreceptor cells by light microscopy. Severe retinal damage was seen by ophthalmoscopy, electroretinography, and light microscopy in three of four eyes receiving 75 micrograms of tissue plasminogen activator and in all eyes treated with 100 micrograms of tissue plasminogen activator or equivalent vehicle. These results suggest that the commercial recombinant tissue plasminogen activator formulation has a narrow margin of safety in nonvitrectomized eyes and that a component of the vehicle is the toxic factor.
Similar articles
-
Retinal toxicity of intravitreal tenecteplase in the rabbit.Br J Ophthalmol. 2004 Apr;88(4):573-8. doi: 10.1136/bjo.2003.027466. Br J Ophthalmol. 2004. PMID: 15031179 Free PMC article.
-
Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes.Arch Ophthalmol. 1991 May;109(5):718-22. doi: 10.1001/archopht.1991.01080050134044. Arch Ophthalmol. 1991. PMID: 1902663
-
Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes.Arch Ophthalmol. 2000 May;118(5):659-63. doi: 10.1001/archopht.118.5.659. Arch Ophthalmol. 2000. PMID: 10815158
-
A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.Am J Ophthalmol. 1999 Dec;128(6):739-46. doi: 10.1016/s0002-9394(99)00239-1. Am J Ophthalmol. 1999. PMID: 10612511
-
Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat.Arch Ophthalmol. 1991 Dec;109(12):1731-6. doi: 10.1001/archopht.1991.01080120115039. Arch Ophthalmol. 1991. PMID: 1841586
Cited by
-
Comparison of treatment methods for submacular hemorrhage in neovascular age-related macular degeneration: conservative versus active surgical strategy.Sci Rep. 2022 Sep 1;12(1):14875. doi: 10.1038/s41598-022-18619-5. Sci Rep. 2022. PMID: 36050401 Free PMC article.
-
Successful displacement of a traumatic submacular hemorrhage in a 13-year-old boy treated by vitrectomy, subretinal injection of tissue plasminogen activator and intravitreal air tamponade: a case report.BMC Ophthalmol. 2015 Aug 7;15:94. doi: 10.1186/s12886-015-0090-3. BMC Ophthalmol. 2015. PMID: 26250101 Free PMC article.
-
Retinal toxicity of intravitreal tenecteplase in the rabbit.Br J Ophthalmol. 2004 Apr;88(4):573-8. doi: 10.1136/bjo.2003.027466. Br J Ophthalmol. 2004. PMID: 15031179 Free PMC article.
-
The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.Br J Ophthalmol. 2007 Aug;91(8):1077-82. doi: 10.1136/bjo.2006.111260. Epub 2007 Mar 23. Br J Ophthalmol. 2007. PMID: 17383998 Free PMC article.
-
Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration.J Ophthalmol. 2021 Nov 2;2021:2963822. doi: 10.1155/2021/2963822. eCollection 2021. J Ophthalmol. 2021. PMID: 34765261 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources